The PI3K/Akt/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles-Reference-Cited by-同舟云学术

The PI3K/Akt/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles

Published:2022-04 Issue: Volume:18 Page:101364
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Sanaei Mohammad-Javad,Razi Sara,Pourbagheri-Sigaroodi Atieh,Bashash Davood^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference179 articles.

1. The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations-the Lung Cancer mutation consortium (LCMC2);Aisner;Clin. Cancer Res.,2018

2. Lung Cancer 2020: epidemiology, etiology, and prevention;Bade;Clin. Chest Med.,2020

3. Ginkgolic acid inhibits invasion and migration and TGF-β-induced EMT of Lung Cancer cells through PI3K/Akt/mTOR inactivation;Baek;J. Cell. Physiol.,2017

4. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions;Balsara;Carcinogenesis,2004

5. A phase I open-label study to identify a dosing regimen of the Pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers;Banerji;Clin. Cancer Res.,2018

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis, biological screening, and binding mode analysis of some N-substituted tetrahydroquinoline analogs as apoptosis inducers and anticancer agents;Journal of Molecular Structure;2024-12

2. Alkaloid-based modulators of the PI3K/Akt/mTOR pathway for cancer therapy: Understandings from pharmacological point of view;Chemico-Biological Interactions;2024-10

3. SPDEF drives pancreatic adenocarcinoma progression via transcriptional upregulation of <i>S100A16 </i>and activation of the PI3K/AKT signaling pathway;Biomolecules and Biomedicine;2024-09-06

4. Chrysin-functionalized gold nanoparticles and paclitaxel exhibit synergistic impact on lung cancer cell lines via regulating the AKT/PPAR-ϒ/β-catenin pathway;Drug Development and Industrial Pharmacy;2024-09-03

5. IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer;Heliyon;2024-09